Analgesic and nonsteroidal anti-inflammatory use in relation to nonmelanoma skin cancer: A population-based case-control study - 28/07/11
![](/templates/common/images/mail.png)
![](/templates/common/images/entites/lowast.gif)
Abstract |
Background |
Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are potentially chemopreventive.
Objective |
We examined the relation between NSAID use and nonmelanoma skin cancer in a population-based case-control study.
Methods |
NSAID and analgesic use was analyzed in 1484 participants: 535 with squamous cell carcinoma (SCC), 487 with basal cell carcinoma (BCC), and 462 control subjects.
Results |
Use of NSAIDs, particularly aspirin, was associated with a reduced odds ratio (OR) of SCC, especially tumors positive for p53 (OR 0.29; 95% confidence interval 0.11-0.79) or with PTCH loss of heterozygosity (OR 0.35; 95% confidence interval 0.13-0.96). Although not considered a NSAID, decreased ORs of both basal cell carcinoma and SCC were observed in relation to use of paracetamol (acetaminophen). Risk of BCC was unrelated to NSAID use.
Limitations |
Self-reported drug use was a limitation.
Conclusions |
This study supports the hypothesis that NSAIDs, aspirin in particular, may reduce risk of SCC and may affect specific molecular subtypes of SCC.
Le texte complet de cet article est disponible en PDF.Key words : basal cell carcinoma, case-control study, nonmelanoma skin cancer, nonsteroidal anti-inflammatory drug, p53, PTCH, squamous cell carcinoma
Abbreviations used : BCC, CI, COX, HR, LOH, NMSC, NSAID, OR, SCC, UVR
Plan
Supported in part by grants CA118443 and CA57494 of the National Institutes of Health, National Cancer Institute and the National Institute of Arthritis and Musculoskeletal and Skin Diseases. |
|
Conflicts of interest: None declared. |
Vol 65 - N° 2
P. 304-312 - août 2011 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?